Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by recurrent viral skin infections. Recent studies have demonstrated that the skin of people with AD my have decreased antimicrobial peptide (AMP) expression. The purpose of this study is to compare smallpox virus replication and the number of AMPs and other antiviral molecules in people with AD, as compared to those seen in people with psoriasis or asthma, or healthy individuals.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus (ADVN AMP01)|
- Expression of vaccinia virus mRNA in non-lesional skin following inoculation with untreated vaccinia virus will be evaluated using real-time RT-PCR (Reverse transcription polymerase chain reaction). [ Time Frame: 5 years ] [ Designated as safety issue: No ]
- Expression of cytokines, AMPs, other antiviral molecules, or epidermal differentiation proteins in non-lesional skin prior to and after inoculation with vaccinia virus will be evaluated using real-time RT-PCR. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
- Keratinocytes will be stimulated with vaccinia virus in the presence and absence of Th1 or Th2 cytokines. Non-lesional AD skin will be stimulated with vaccinia virus in the presence of antibodies that neutralize Th2 cytokines. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
- Vaccinia virus replication will be evaluated using a standard viral plaque assay in BS-C-1 cells and by analyzing vaccinia virus mRNA expression using real-time RT-PCR in keratinocytes and BS-C-1 cells. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
- Expression of over 20,000 genes will be evaluated by GeneChip microarrays in non-lesional skin, and PBMCs stimulated with vaccinia virus. Real-time RT-PCR of skin and PBMC will be used to confirm gene alterations found in GeneChip microarrays. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
- Ability of structural analogues of CSAs (Cyclosporine) to kill purified vaccinia virus as well as keratinocytes infected with vaccinia virus in vitro. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood and skin samples will be retained
|Study Start Date:||June 2005|
|Study Completion Date:||February 2010|
|Primary Completion Date:||February 2010 (Final data collection date for primary outcome measure)|
Active Atopic Dermatitis (AD)
Pediatric and adult subjects who fulfill the criteria for AD, a chronic inflammatory skin disease.
Inactive Atopic Dermatitis (AD)
Adult subjects with a prior history of active AD that has been quiescent for at least 1 year.
Adult subjects who fulfill the criteria for plaque psoriasis, a chronic inflammatory skin disease.
Asthmatics (without a history of AD)
Adult subjects who fulfill the criteria for asthma (reactive airway disease) and have a negative history of skin disease.
Eczema Herpeticum (EH
Pediatric and adult AD subjects with a history of EH.
Healthy individuals with no history of skin or respiratory disease.
AD is a chronic inflammatory skin disease characterized by frequent viral skin infections. Recent studies have found that components in the skin of people with AD may block AMP expression. AMPs are responsible for preventing infection from viruses. The purpose of this study is to examine smallpox virus replication and AMP expression in the skin of patients with AD as well as identify other antiviral molecules involved in immune response. These findings will be compared with those of people with psoriasis or asthma, or healthy individuals. This study will consist of one study visit at which skin and blood samples will be taken.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00407069
|United States, Colorado|
|National Jewish Health|
|Denver, Colorado, United States, 80207|
|Principal Investigator:||Donald Leung MD, PhD||National Jewish Health|